Maze Therapeutics, Inc. (NASDAQ:MAZE) Short Interest Update

Maze Therapeutics, Inc. (NASDAQ:MAZE) was the recipient of a large increase in short interest during the month of September. As of September 30th, there was short interest totaling 2,460,000 shares, an increase of 50.9% from the September 15th total of 1,630,000 shares. Currently, 12.6% of the company’s shares are sold short. Based on an average daily volume of 440,500 shares, the days-to-cover ratio is presently 5.6 days. Based on an average daily volume of 440,500 shares, the days-to-cover ratio is presently 5.6 days. Currently, 12.6% of the company’s shares are sold short.

Insiders Place Their Bets

In related news, Director Richard H. Scheller sold 20,744 shares of the stock in a transaction on Monday, September 15th. The stock was sold at an average price of $22.37, for a total transaction of $464,043.28. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Alphabet Inc. purchased a new stake in Maze Therapeutics in the 1st quarter worth approximately $26,561,000. Invesco Ltd. acquired a new position in shares of Maze Therapeutics in the 1st quarter valued at $226,000. Goldman Sachs Group Inc. acquired a new position in shares of Maze Therapeutics in the 1st quarter valued at $145,000. Nuveen LLC purchased a new stake in Maze Therapeutics during the first quarter worth $125,000. Finally, Bank of New York Mellon Corp acquired a new stake in Maze Therapeutics during the first quarter valued at $190,000.

Maze Therapeutics Stock Down 1.4%

Shares of Maze Therapeutics stock opened at $29.12 on Thursday. The company has a 50 day moving average price of $21.63 and a 200 day moving average price of $15.24. Maze Therapeutics has a 52 week low of $6.71 and a 52 week high of $31.93.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.02.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on MAZE shares. BTIG Research increased their target price on shares of Maze Therapeutics from $30.00 to $37.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Maze Therapeutics in a research note on Thursday, September 18th. Wedbush started coverage on Maze Therapeutics in a research report on Tuesday, July 8th. They set an “outperform” rating and a $17.00 target price for the company. Finally, JPMorgan Chase & Co. upped their target price on Maze Therapeutics from $27.00 to $37.00 and gave the company an “overweight” rating in a research note on Monday, September 29th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $33.83.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.